TWiki . Edumacation . StockPumpingMarketNewscastHtds	TWiki . { Main | Edumacation | TWiki | Test }
	Edumacation . { Home | Users | Changes | Search | Go }

Received: from jeans ([69.56.194.130]) by mc7-f39.hotmail.com with Microsoft SMTPSVC(5.0.2195.6713);
    Mon, 13 Oct 2003 21:04:13 -0700
From: "info@marketnewscast.net" <dhuease3@hotmail.com>
To: "mantell5" <mantell5@hotmail.com>
Subject: Market Newscast 
Messege-ID: <QRNIA493zC$9MU3=4ICCC$JMR4SV9F@jeans>
MIME-Version: 1.0
Content-type: text/html; charset=windows-1252

COMPANY PROFILE OF THE MONTH HARD TO TREAT DISEASES, INC Hard to Treat Diseases, Inc., ("HTTD") which trades on the Over-the-Counter market under the symbol: HTDS, is a fascinating company with great emphasis on fighting cancer. The company announced several press releases to the public in the past months and it seems like HTTD is very focused in bringing a cancer fighting drug to market, named TubercinR. TubercinR has a US medical Patent, under patent number 6,274,356. The unique properties unlike other cancer products are clearly stated in the abstract summary of the "A carbohydrate complex, which is a mixture of low molecular-weight polysaccaharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects". In a recent report on TubercinR Therapy published in The Newest Medical Journal, Vol. 46, No. 1 . 3, 2003 January - March. The report, Immunotherapy Against Malignant Tumor - Emphasis on Tubercin Therapy, discusses the results of certain patients treated from Surgical Operation, Chemotherapy, Radiotherapy and TubercinR. On page 41 of the report, it states in 7 cases of Mucosal Malignant Melanoma arising in the nasal cavity, 2 cases were treated with TubercinR after surgical treatment. The disease-free survival time in 2 patients who were treated with TubercinR was 7 years and 3 years respectfully. It was much longer than in 5 patients who were treated without TubercinR whose mean disease-free survival time was less than one year. Also stated on page 47 of the report, " TubercinR is one of the rare medications that could serve as a preventative measure against cancers that may arise due to immuno-deficiency." OCTOBER 2003 OTC SYMBOL: HTDS SUBSCRIBE NEWSLETTER Last month we featured OTCBB: CYPT and the stock was trading at .68 and now its is trading at $1.34 on October 8 2003 DISCLAIMER Per Section 17(b) of the Securities Act of 1933: Market Newscast, a marketing company, was paid two thousand five hundred dollars for the creation & distribution of this advertisement, by a non-affiliated, third party. The advertisement is for marketing purposes only & does not have regard to investment objective, financial situation or suitability. This advertisement is based on HTTD's website and press releases. Market Newscast does not verify the accuracy of such releases. This advertisement is NOT the opinion of HTTD management, which has NOT seen, and does not endorse this advertisement! Consultant a professional investment advisor prior to making any investment decision and to independently verify the information in this advertisement. An investment in HTTD is considered to be highly speculative and could result in a complete loss of investment. Market Newscast is NOT an investment advisor or broker-dealer. Market Newscast accepts no liability for any loss arising from an investor's reliance on or use of this advertisement. This advertisement is not intended to be, and shall not constitute, an offer to sell or solicitation of any offer to buy any security. Certain statements contained herein are "forward-looking" statements and investors are cautioned that any such forward-looking statements could involve risks and uncertainties, or may never materialize. HTTD will require additional capital to realize its business plan and continue as a going concern. Consult with your financial advisor about HTTD for further details concerning these risks and uncertainties. To be removed from our mailing list ..Please send an email to unsubscribe@marketnewscast.net

file attachment:	action:	size:	date:	who:	comment:
blanc.gif	view update	43	13 Oct 2003 - 07:11	EliMantel	white space
editor1_title.gif	view update	996	13 Oct 2003 - 07:06	EliMantel	"from the editor" signature
lightblueback.gif	view update	53	13 Oct 2003 - 06:58	EliMantel	light blue background
ntop.jpg	view update	20766	13 Oct 2003 - 06:51	EliMantel	newsletter header
referfriend.gif	view update	1337	13 Oct 2003 - 06:59	EliMantel	refer a friend banner
sidebar_profile.gif	view update	648	13 Oct 2003 - 06:59	EliMantel	update profile sidebar
top2.jpg	view update	37670	13 Oct 2003 - 06:48	EliMantel	Market Newscast banner
verticalblue1px.gif	view update	46	13 Oct 2003 - 06:58	EliMantel	vertical blue bar
	add

Topic StockPumpingMarketNewscastHtds . { Edit | Ref-By | Attach | Diffs | r1.2 | > | r1.1 }

You must register before editing pages or using other extended features on this TWiki system.

Revision r1.2 - 13 Oct 2003 - 06:47 by EliMantel  Privacy Policy

Copyright © 2000-2005 by the contributing authors. All material on this collaboration tool is the property of the contributing authors. Collect email addresses here. Ideas, requests, problems regarding TWiki? Send feedback.